vs
Side-by-side financial comparison of Dexcom (DXCM) and ESAB Corp (ESAB). Click either name above to swap in a different company.
Dexcom is the larger business by last-quarter revenue ($1.3B vs $727.8M, roughly 1.7× ESAB Corp). Dexcom runs the higher net margin — 21.2% vs 7.5%, a 13.7% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs 8.5%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs 2.8%).
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
ESAB, Elektriska Svetsnings-Aktiebolaget, is an American-Swedish industrial company.
DXCM vs ESAB — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $727.8M |
| Net Profit | $267.3M | $54.8M |
| Gross Margin | 62.9% | 37.0% |
| Operating Margin | 25.6% | 14.6% |
| Net Margin | 21.2% | 7.5% |
| Revenue YoY | 21.6% | 8.5% |
| Net Profit YoY | 153.6% | 2.1% |
| EPS (diluted) | $0.67 | $0.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $727.8M | ||
| Q3 25 | $1.2B | $715.6M | ||
| Q2 25 | $1.2B | $678.1M | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $1.1B | $670.8M | ||
| Q3 24 | $994.2M | $673.3M | ||
| Q2 24 | $1.0B | $707.1M |
| Q1 26 | $267.3M | — | ||
| Q4 25 | $267.3M | $54.8M | ||
| Q3 25 | $283.8M | $66.9M | ||
| Q2 25 | $179.8M | $67.4M | ||
| Q1 25 | $105.4M | — | ||
| Q4 24 | $151.7M | $53.7M | ||
| Q3 24 | $134.6M | $68.2M | ||
| Q2 24 | $143.5M | $82.9M |
| Q1 26 | 62.9% | — | ||
| Q4 25 | 62.9% | 37.0% | ||
| Q3 25 | 60.5% | 37.2% | ||
| Q2 25 | 59.5% | 37.6% | ||
| Q1 25 | 56.9% | — | ||
| Q4 24 | 58.9% | 38.5% | ||
| Q3 24 | 59.7% | 37.7% | ||
| Q2 24 | 62.4% | 38.2% |
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 14.6% | ||
| Q3 25 | 20.1% | 15.2% | ||
| Q2 25 | 18.4% | 16.2% | ||
| Q1 25 | 12.9% | — | ||
| Q4 24 | 17.0% | 16.6% | ||
| Q3 24 | 15.3% | 15.7% | ||
| Q2 24 | 15.7% | 16.9% |
| Q1 26 | 21.2% | — | ||
| Q4 25 | 21.2% | 7.5% | ||
| Q3 25 | 23.5% | 9.3% | ||
| Q2 25 | 15.5% | 9.9% | ||
| Q1 25 | 10.2% | — | ||
| Q4 24 | 13.6% | 8.0% | ||
| Q3 24 | 13.5% | 10.1% | ||
| Q2 24 | 14.3% | 11.7% |
| Q1 26 | $0.67 | — | ||
| Q4 25 | $0.67 | $0.90 | ||
| Q3 25 | $0.70 | $1.09 | ||
| Q2 25 | $0.45 | $1.10 | ||
| Q1 25 | $0.27 | — | ||
| Q4 24 | $0.37 | $0.87 | ||
| Q3 24 | $0.34 | $1.11 | ||
| Q2 24 | $0.35 | $1.35 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $917.7M | $218.2M |
| Total DebtLower is stronger | — | $1.3B |
| Stockholders' EquityBook value | $2.7B | $2.1B |
| Total Assets | $6.3B | $4.9B |
| Debt / EquityLower = less leverage | — | 0.63× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $917.7M | — | ||
| Q4 25 | $917.7M | $218.2M | ||
| Q3 25 | $1.8B | $258.2M | ||
| Q2 25 | $1.2B | $291.3M | ||
| Q1 25 | $904.9M | — | ||
| Q4 24 | $606.1M | $249.4M | ||
| Q3 24 | $621.2M | $253.7M | ||
| Q2 24 | $939.2M | $228.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B |
| Q1 26 | $2.7B | — | ||
| Q4 25 | $2.7B | $2.1B | ||
| Q3 25 | $2.7B | $2.1B | ||
| Q2 25 | $2.6B | $1.9B | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.1B | $1.8B | ||
| Q3 24 | $2.0B | $1.8B | ||
| Q2 24 | $2.4B | $1.7B |
| Q1 26 | $6.3B | — | ||
| Q4 25 | $6.3B | $4.9B | ||
| Q3 25 | $7.5B | $4.4B | ||
| Q2 25 | $7.3B | $4.2B | ||
| Q1 25 | $6.8B | — | ||
| Q4 24 | $6.5B | $4.0B | ||
| Q3 24 | $6.4B | $4.1B | ||
| Q2 24 | $6.8B | $4.0B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.63× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.55× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.59× | ||
| Q2 24 | — | 0.63× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $81.5M |
| Free Cash FlowOCF − Capex | — | $70.3M |
| FCF MarginFCF / Revenue | — | 9.7% |
| Capex IntensityCapex / Revenue | — | 1.5% |
| Cash ConversionOCF / Net Profit | — | 1.49× |
| TTM Free Cash FlowTrailing 4 quarters | — | $238.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $294.0M | $81.5M | ||
| Q3 25 | $659.9M | $46.6M | ||
| Q2 25 | $303.0M | $35.4M | ||
| Q1 25 | $183.8M | — | ||
| Q4 24 | $301.4M | $126.9M | ||
| Q3 24 | $199.5M | $101.0M | ||
| Q2 24 | $279.4M | $83.0M |
| Q1 26 | — | — | ||
| Q4 25 | $192.1M | $70.3M | ||
| Q3 25 | $579.4M | $37.4M | ||
| Q2 25 | $208.9M | $28.1M | ||
| Q1 25 | $96.8M | — | ||
| Q4 24 | $176.8M | $102.2M | ||
| Q3 24 | $88.3M | $90.4M | ||
| Q2 24 | $213.3M | $74.0M |
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | 9.7% | ||
| Q3 25 | 47.9% | 5.2% | ||
| Q2 25 | 18.1% | 4.1% | ||
| Q1 25 | 9.3% | — | ||
| Q4 24 | 15.9% | 15.2% | ||
| Q3 24 | 8.9% | 13.4% | ||
| Q2 24 | 21.2% | 10.5% |
| Q1 26 | — | — | ||
| Q4 25 | 8.1% | 1.5% | ||
| Q3 25 | 6.7% | 1.3% | ||
| Q2 25 | 8.1% | 1.1% | ||
| Q1 25 | 8.4% | — | ||
| Q4 24 | 11.2% | 3.7% | ||
| Q3 24 | 11.2% | 1.6% | ||
| Q2 24 | 6.6% | 1.3% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 1.49× | ||
| Q3 25 | 2.33× | 0.70× | ||
| Q2 25 | 1.69× | 0.53× | ||
| Q1 25 | 1.74× | — | ||
| Q4 24 | 1.99× | 2.36× | ||
| Q3 24 | 1.48× | 1.48× | ||
| Q2 24 | 1.95× | 1.00× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DXCM
Segment breakdown not available.
ESAB
| Consumable Products | $477.9M | 66% |
| Equipment Products | $249.9M | 34% |
